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ABSTRACT  37 
 38 
Background: Medication safety risks are the most important preventable factors jeopardizing patient 39 
safety. To manage these risks, extending pharmacists’ involvement in patient care and patient safety work 40 
has been systematically addressed in patient safety initiatives since the early 2000s. 41 
 42 
Objective: To explore the extent and range of clinical pharmacy services in Finnish hospitals to promote 43 
medication safety: 1) in 2011, when the first National Patient Safety Strategy, the new Health Care Act and 44 
the Medicines Policy 2020 had been recently enacted; and 2) five years later in 2016. 45 
 46 
Methods: The study was conducted in 2011 and 2016 as a national online survey targeted to hospital 47 
pharmacies (n=24) and medical dispensaries (n=131 in 2011; n=28 in 2016).  The questions were analyzed 48 
using descriptive statistics and qualitative content analysis.  49 
 50 
Results: Overall response rate was 60% in 2011 and 52% in 2016. Clinical pharmacy services were provided 51 
by 51% of the responding units in 2011, whereas by 85% in 2016. The reported number of clinical 52 
pharmacists had increased during the five years. The most notable increase in reported tasks occurred in 53 
conducting medication reconciliations (+63% increase in the number of providing units). By 2016 54 
pharmacists had extended their tasks particularly towards system-based medication safety work: e.g. 55 
developing instructions for medication-use (91% of the responding units), creating and updating 56 
medication safety plans (87%) and using medication error reports in developing the process of medication 57 
use safer (78%). Pharmacists’ participation in long-term continuing education became more common in 58 
2016, which was perceived as helpful in extending their responsibilities to improve medication safety. 59 
 60 
Conclusion: Pharmacists’ involvement in patient care and system-based medication safety work was 61 
reported to become more common in Finnish hospitals during 2011-2016. This development is in line with 62 
patient safety policy initiatives and its impact on patient care outcomes should be followed up.   63 
 64 
 65 
 66 
 67 
 68 
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1. INTRODUCTION 69 
 70 
Pharmacotherapy is one of the most common interventions in healthcare. Even effective, 71 
pharmacotherapies used in hospitals are often challenging to manage: approximately 6% of hospitalized 72 
patients experience an adverse drug event during their hospital stay.1 In many cases, medications used in 73 
hospitals are parenterally administered, which increases a risk for medication errors (MEs).2-3 Furthermore, 74 
hospitalized patients are often unstable and need intensive and continuous monitoring, as well as fast 75 
clinical decision-making. System-based patient safety work has shown that medication errors are one of the 76 
most important preventable factors jeopardizing patient safety in healthcare.4-7 To be safe, 77 
pharmacotherapies used in hospitals require well-designed care processes both for individual patients and 78 
at the organizational level. Therefore, international patient safety initiatives prioritize strategies and 79 
policies to improve safe medication practices. 4-7 These strategies have emphasized the creation of a safety 80 
culture, learning from medication errors through reporting systems and development of preventive actions 81 
for prospective risk management. 82 
 83 
The Council of Europe was among the first ministry level institutions in Europe to establish 84 
recommendations to improve medication safety as part of patient safety in 2006.5-6 These medication 85 
safety recommendations focused on safety culture and considered e.g. early detection of adverse drug 86 
events, the setup of medication error reporting systems, strengthening awareness and learning of 87 
professionals, introducing electronic prescribing, improving naming, labelling and packaging, and improving 88 
medicines information practices. Council of Europe has continued its long-term commitment to medication 89 
safety work under the European Directorate of Quality of Medicines (EDQM) with a program to create 90 
pharmaceutical care indicators.8-9 Also, European Union (EU) and its stakeholder organizations have 91 
coordinated efforts to encourage the member countries to take actions to improve patient and medication 92 
safety.10-11 Most lately EU integrated medication safety with drug safety, i.e. pharmacovigilance initiatives 93 
through a Directive enacted in 2012.12  94 
 95 
All the patient and medication safety initiatives, recommendations and policies over the years have been 96 
based on interprofessional team work principles.4-7 As pharmacists as healthcare professionals are 97 
specialized in pharmacotherapies, they have been encouraged to take more responsibility of managing safe 98 
medication practices in different settings. E.g. EDQM invited European governments and policy-makers to 99 
implement the principles and working methods of clinical pharmacy and pharmaceutical care in their 100 
national healthcare systems.8-9 Clinical pharmacy is an area of pharmacy concerned with the science and 101 
practice of rational and appropriate medication use.13-14 According to the principles of pharmaceutical care, 102 
pharmacists are expected to ensure the quality and safety of medication therapies in patient care, with 103 
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emphasis on collaborative care and patient interaction.14-17 Even though pharmaceutical care and patient-104 
centered clinical pharmacy services have been shown to improve quality, safety and efficiency of care and 105 
reduce its costs,18-21  their diffusion to many healthcare systems, e.g. in Europe,22 has been slow. Growing 106 
evidence of patient safety risks cumulating from medications, also in Finnish healthcare, have created a 107 
need to develop new strategies and policies to manage these risks.23-26  The aim of this study was to explore 108 
the extent and range of clinical pharmacy services in Finnish hospitals to promote medication safety: 1) in 109 
2011, when the first National Patient Safety Strategy27, the new Health Care Act28 and the Medicines Policy 110 
202024 had been recently enacted; and 2) five years later in 2016. 111 
 112 
2. MATERIALS AND METHODS 113 
 114 
2.1. Context of the study 115 
In Finland municipalities are responsible for organizing primary healthcare services, which are mainly 116 
provided by municipal health centers.28 The secondary special healthcare is organized by central hospitals, 117 
each of them located in their own hospital districts (n=21) covered by federations of municipalities 118 
(including Åland). For special tertiary healthcare, Finland is divided into five responsibility areas, each with a 119 
university hospital. Private healthcare services complete the public health services. Hospital pharmacies 120 
(n=24) are located in university hospitals, central hospitals and in some larger health centers with inpatient 121 
wards. Medicine dispensaries supply medicines in smaller inpatient healthcare units in the public and 122 
private sectors. Some of them operate independently as part of the healthcare organization and others in 123 
the public sector operate under hospital pharmacies. The number of medicine dispensaries had remarkably 124 
decreased from 94 to 55 between 2011 and 2016 (Finnish Medicines agency, unpublished statistics 2012), 125 
while the number of hospital pharmacies (n=24) remained the same.29-30 The number of independent 126 
medicine dispensaries decreased   because of a strategic trend to merge small medicine dispensaries into 127 
larger hospital pharmacies in the region. The goal of the merges was to release resources from 128 
administrative and logistic work to be reallocated to more patient care oriented clinical pharmacy services.  129 
 130 
Clinical pharmacy as a concept was defined in Finland in 2010 for initiating a national specialization 131 
program for hospital and health center pharmacists with special reference to systems approach to patient 132 
and medication safety.31 The following definition was constructed based on an inventory of definitions by 133 
key international clinical pharmacy organizations: Clinical pharmacy is a health science focusing on 134 
pharmacists’ contributions to medicines optimization and health promotion.  Clinical pharmacy emphasizes 135 
rational medicine use and promoting it, development and evaluation of pharmaceutical services, medicines 136 
management, and medication safety. Prerequisites for clinical pharmacy are interprofessional collaboration 137 
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and collaboration with patients. Clinical pharmacy covers all social and healthcare settings in inpatient and 138 
outpatient care where pharmacotherapy is part of the care of the patients.  The concept “ward pharmacy” 139 
has a longer history in Finland and it has been defined as “a medication management at hospital wards 140 
conducted by pharmaceutical staff”.24 The ward pharmacy as a concept reflects the long-time core mission 141 
of Finnish hospital pharmacists in the management of medicines supply and logistics.32-34 The first clinical 142 
pharmacy posts in Finnish hospitals were established in the end of the 1980s, but the development of 143 
clinical pharmacy services has been slow.33-34 Moreover, pharmacy education in Finland, as in many other 144 
countries, has not prepared pharmacists to be involved in patient care and to provide clinical pharmacy 145 
services as a part of the healthcare team.35-36 The first steps towards more systematic training in 146 
pharmacists’ clinical skills were taken through national accreditation training for comprehensive medication 147 
reviews which started in 2005.37 It has had spillover effects on undergraduate training, specialization 148 
training of community and hospital pharmacists, and practice development.  149 
 150 
In Finland, increasing pharmacists’ involvement in patient care and assuring safe medication practices in 151 
hospitals was recommended for the first time in 2006 when Ministry of Social Affairs and Health guided 152 
each healthcare unit to set up a medication safety plan, i.e., an organization-based medication risk 153 
management plan.23 The plan should have a description of the system, processes, resources and persons in 154 
charge for safe pharmacotherapies.   The plan became obligatory as part of the patient safety risk 155 
management plan in 2011 when the new Health Care Act was enacted.28 Implementation of these patient 156 
and medication safety initiatives were supported by the National Patient Safety Program in 2011-2014.27 157 
The Medicines Policy 2020, established in 2011, also supported the same strategic objectives with special 158 
emphasis on the pharmaceutical sector’s contributions to safe and rational pharmacotherapy.24 The 159 
recommended actions have been conveyed through international recommendations, particularly by The 160 
Council of Europe,5-6 The European Union,10-11 WHO,38 research data derived from reporting systems for 161 
patient safety incidents,25,39 and benchmarking best practices.      162 
 163 
2.2. Study design and method 164 
This study was conducted as a national online survey targeted at all hospital pharmacies and medicine 165 
dispensaries serving inpatient healthcare units. The survey was first conducted in 2011 and repeated in 166 
2016 for a follow-up of developments.  167 
 168 
2.3. Development of the survey instrument 169 
Six semi-structured theme interviews were conducted to develop the survey instrument in 2011. The 170 
interviewees were selected by purposive sampling to present the widest range of clinical pharmacy services 171 
in Finnish hospitals at that time. Recruitment was facilitated by the Finnish Pharmacists’ Association and 172 
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the Faculty of Pharmacy, University of Helsinki, Finland. Interviewees were working on the wards or as 173 
leaders of clinical pharmacy teams in different hospitals and health centers with inpatient wards. In 174 
addition to the interviews, information gathered from practice development projects in Finland and 175 
international scientific literature was used for developing the survey instrument. Definitions for clinical 176 
pharmacy,13-14 pharmaceutical care,15-17 and patient and medication safety from systems approach5-6 were 177 
used to outline the range of services included in the structured list of the survey instrument.  Medication 178 
safety and prospective risk management aspects were emphasized in the selection of the tasks and 179 
services.5-6,40-41 In order to get a better understanding of the evolution of pharmacists’ contributions to 180 
patient care and medication safety a detailed list of tasks (n=29) was developed. The more detailed list was 181 
expected to increase sensitivity of the measures compared to using general statements of services, such as 182 
counseling patients on their medications, or checking and reviewing medications.  As Finnish hospital 183 
pharmacists do not have a long history in providing other than logistic services, we intentionally included 184 
also clinical tasks that are not so “advanced” but reflect merely early phase of clinical pharmacy service 185 
implementation in the 1960s, e.g., provision of drug information to ward personnel.  These services are still 186 
an important part of the infrastructure needed for medication safety and risk management.41 They also can 187 
perform as indicators for transition from early phase clinical pharmacy services towards more advanced 188 
and sophisticated ones. The list of tasks and services included in the survey is presented in Figure 3.   189 
 190 
The final survey instrument was divided into three parts: 1) questions gathering background information on 191 
the respondent’s healthcare organization; 2) questions for hospital pharmacies/medicine dispensaries 192 
providing clinical pharmacy services to inpatient care; and 3) questions for non-providers of clinical 193 
pharmacy services (Figure 1). The questions employed a five-point Likert scale, multiple choice questions 194 
and open fields for responses.  Structured questions were used to gather the background information of 195 
the responding units, the current range of clinical pharmacy services provided, how they are planned and 196 
managed, and the evaluated benefits and outcomes (if studied in the responding unit) of these services. 197 
The survey instrument was piloted for content and face-validity with three clinical pharmacists from 198 
separate organizations. Time required for responding to the survey varied between 10-40 minutes 199 
depending on the range of the services provided by the respondent’s organization.  200 
 201 
The same online survey instrument was utilized in the follow-up survey in 2016 (Figure 1). Most of the 202 
questions remained the same, but some of the open-ended questions were changed to structured 203 
questions in 2016. The structured list of clinical pharmacy services was updated (Figure 3) for the survey in 204 
2016 by adding 12 services implemented after the first survey in 2011. Furthermore, the updated list also 205 
contained such clinical pharmacy services that were set as a goal by the European Association of Hospital 206 
Pharmacists (EAHP) for delivering hospital pharmacy services in every European health system.42 In 2011, 207 
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the respondents were asked to submit any available reports on the studies they had conducted to show the 208 
outcomes of the services they provided. Reports received in 2011 (n=9) were used to develop a structured 209 
list of benefits and outcomes to the 2016 survey (see Figure 6).  210 
 211 
2.4. Conducting the survey in 2011 and 2016 212 
The online survey was conducted in 2011 and in 2016. The survey was e-mailed to all chief hospital 213 
pharmacists (n=24 in 2011 and 2016) and all managers of the medicine dispensaries (n= 94 in 2011 and 214 
n=55 in 2016). The e-mail addresses of the chief hospital pharmacists were received from the Faculty of 215 
Pharmacy, University of Helsinki. The managers of the medicine dispensaries were contacted using the 216 
membership register of The Finnish Pharmacists’ Association provided by the officer of the Association.  217 
While there were 55 managers of medicine dispensaries in 2016, only the managers of the independent 218 
ones, not managed by hospital pharmacies, were invited to participate in the survey (n=28 out of 55 219 
managers). This is because information on clinical pharmacy services provided by the non-independent 220 
medicine dispensaries were covered by the responses from the hospital pharmacies under which they 221 
opera ted.  The chiefs and managers were asked to forward the survey to the pharmacists in their 222 
organization who provided or managed clinical pharmacy services so that that there would be one 223 
coordinated response per organization. The survey was planned to be open for two weeks and two 224 
reminders were sent during that period. After the period, a third e-mail reminder was sent, and the survey 225 
was extended to be open for one more week for responses. 226 
 227 
2.5. Data analysis  228 
The structured questions were analyzed with descriptive statistics using Microsoft Excel.43 The responses 229 
from hospital pharmacies and medicine dispensaries were analyzed separately to identify differences in the 230 
operations of these units. Likewise, in some questions the responses from hospital pharmacies were 231 
divided into university hospitals, central hospitals and community hospitals to identify differences between 232 
these hospital pharmacies. The open-ended questions were analyzed by applying a conventional content 233 
analysis.44 Systems approach to human errors and risk management as illustrated in the Reason’s Human 234 
Error Theory was applied to illustrate reported tasks where clinical pharmacists contributed to medication 235 
safety at all stages of the medication-use process.45 236 
 237 
2.6. Study ethics 238 
According to the scientific ethical guidelines in Finland, an ethics committee approval was not required for 239 
a survey without patient data.46 The survey participants were informed that the participation was voluntary 240 
and responding to the survey implied an informed consent. The invitation to participate in the survey was 241 
sent by e-mail, including a cover letter with a description of the study and a link to an online questionnaire. 242 
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Detailed information of the responding organizations was not asked for, only whether the unit was a 243 
hospital pharmacy or a medication dispensary and the county in which the unit was located. All responses 244 
were confidential. 245 
 246 
3. RESULTS  247 
3.1. Survey participants and coverage 248 
In 2011, the responses were received from 20/24 of the hospital pharmacies (83%) and 51/94 medicine 249 
dispensaries (54%), yielding an overall response rate of 60% (n=71/118). In 2011, the hospital pharmacies 250 
were not asked if they were university, central or community hospital pharmacies, but the total coverage 251 
was 83%.  In 2016, 18/24 of hospital pharmacies (75%) and 9/28 of the independent medicine dispensaries 252 
(32%) responded to the follow-up survey resulting in an overall response rate of 52% (n=27/52, Figure 2). 253 
Among the respondents in 2016 were all five university hospital pharmacies (100%), 13 central hospital 254 
pharmacies and one community hospital pharmacy (Figure 2) covering 74% (n=14/19) of the central and 255 
community hospital pharmacies, which provide clinical pharmacy services to the largest inpatient 256 
healthcare units. 257 
 258 
3.2. Reported clinical pharmacy services in 2016 compared to 2011 259 
 260 
The relative number of responding units providing clinical pharmacy services increased during 2011-2016 261 
from 51% to 85% (Table 1). Thus, the proportion of the units reporting non-provision of clinical pharmacy 262 
services decreased from 49% in 2011 to 15% in 2016. The main reported reason for not providing clinical 263 
pharmacy services was the small number of pharmacy staff, which was commonly 1-2 pharmacists in 264 
medicine dispensaries. The reported number of clinical pharmacists and hospital units receiving clinical 265 
pharmacy services had increased during the five-year study period (Table 1). More typically they were 266 
reported to split their work time between 2-3 units both in 2011 and 2016, only a small number of the 267 
clinical pharmacists were reported to work in one unit (ward, clinic).  According to the responses of the 268 
both surveys, the services were most commonly available in surgical and internal medicine wards. All five 269 
university hospitals reported having clinical pharmacy services in intensive care, pediatric and oncology 270 
units in 2016.  271 
 272 
3.2.1 Evolution of reported tasks of clinical pharmacists 273 
Reported tasks performed by clinical pharmacists in 2011 and 2016 are presented in Figure 3. The figure 274 
shows extension and implementation of the new tasks, most of which were related to improving 275 
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medication safety. Of the twelve reported new tasks in 2016, most widely performed were tasks assuring 276 
medication safety at the organizational level, such as developing instructions for medication use and 277 
medication therapy (91% reported), taking part in creating and updating medication safety plans (87%), 278 
taking part in multiprofessional working groups (87%) and developing medication-use processes by using 279 
data from medication error reports (78%, Figure 3). In 2016 clinical pharmacy services covered all crucial 280 
stages of the medication-use process (Figure 4).  The reported major new contributions within the five 281 
years period was the new role in developing, auditing and instructing the medication use-process with the 282 
system approach,45 conducting medication reconciliations (+63%) and counselling patients (+39%, Figure 3).  283 
 284 
Clinical pharmacists were reported having access to patient records in almost all (96%) and access to 285 
laboratory results in the majority (83%) of the responding units in 2016 (this was not asked in 2011). The 286 
proportion of logistic tasks (e.g. ordering and stock control) remained the same (83% reported, Figure 3). In 287 
2016, the respondents were asked to estimate how much time was spent on logistic tasks compared to 288 
other tasks. More than half (59%, n=16) of the respondents estimated that 5-50% of the time was spent on 289 
logistic tasks, while in almost one-third of the units (30%, n=8), less than 5% of the working time was used. 290 
A variation between the tasks of different clinical pharmacists was reported: some performed only logistic 291 
tasks, while others had none.  Additionally, the respondents reported in an open question their perceptions 292 
about the most important tasks actually performed by the clinical pharmacists in their organization at the 293 
time of the survey: drug information to ward personnel (48%, n=13), medication reconciliation (33%, n=9), 294 
inducting ward personnel (26%, n=7), and developing the medication-use process (22%, n=6). 295 
 296 
3.2.2 Strategy, management and future plans of clinical pharmacy services  297 
In 2011, less than half (42%) of the responding units reported having a manager dedicated to clinical 298 
pharmacy services, while in 2016 the majority (74%) reported this (Table 1). A plan or strategy for clinical 299 
pharmacy services was reported to been devised in 20% of the responding units in 2011, while in 63% of 300 
the units in 2016 (Table 1). In 2016, half of the responding units (52%) were familiar with the European 301 
Statements of Hospital Pharmacy42 that could be utilized to guide the development of a strategy for 302 
hospital pharmacy services. 303 
 304 
Both in 2011 and 2016, the most common plan for the future in the responding hospital pharmacies and 305 
medicine dispensaries was reported to be to extend the clinical pharmacy services to new care units within 306 
their healthcare organization. In 2016, almost half (44%) of the responding units reported to have a plan to 307 
re-develop and extend the clinical pharmacists’ role to be more clinical and patient-oriented. Similar plans 308 
were reported already in 2011, but a need for continuing education to adopt a more patient oriented role 309 
was recognized. The use of information and automation technology was reported as a key in changing the 310 
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logistics role of clinical pharmacists in both years.  In 2016, 30% of the respondents had the opinion that 311 
clinical pharmacy services should increasingly be provided in primary care, nursing homes, home care and 312 
social care units. Additionally, in 2016, almost two-thirds (62%) of the responding units thought that 313 
pharmacists could take a position as medication safety officers or coordinators in the future, while the rest 314 
(38%) had no opinion. 315 
 316 
3.3 Reported importance of continuing education  317 
Participation in long-term continuing education was reported to have been increased during 2011-2016 318 
(Figure 5). Only one hospital pharmacy and one medicine dispensary reported that their clinical 319 
pharmacists had not participated in any long-term continuing education by 2016. It was perceived that the 320 
clinical pharmacists were able to use the expertise acquired through the long-term continuing education 321 
well (70% of the responding units) or slightly (30%). Almost half (48%) of the respondents thought that 322 
participating in continuing education had supported the development of the patient-centered tasks of 323 
clinical pharmacists. 324 
 325 
3.4 Assessed benefits and outcomes of clinical pharmacy services 326 
Of the responding units, 33% (n=9) reported having assessed the benefits and outcomes of clinical 327 
pharmacy services since 2011 (Figure 6). The results were typically reported internally to their own 328 
organization (n=7), in the national congresses (n=4) or in national scientific journals (n=2). Increased 329 
multiprofessional collaboration, saved working time of nurses and savings in drug consumption were the 330 
most commonly reported assessed and achieved benefits and outcomes in 2011 and 2016.  In 2016, 331 
common patient safety benefits which were not surveyed or reported in 2011 were the increased reporting 332 
of medication errors (n=5) and increased number of accurate medication charts (n=5). 333 
 334 
 335 
4. DISCUSSION  336 
 337 
Responses to this national study suggest changes in the pharmacists’ involvement in patient care and 338 
assuring medication safety in Finnish hospitals within a time period of five years in 2011-2016. This change 339 
can be seen in the workforce resources and tasks performed by clinical pharmacists in care units (Figure 3, 340 
Figure 4). Their contributions were reported to be extended towards interventions prioritized in 341 
international and national patient and medication safety recommendations. Also, clinical pharmacists’ 342 
competences were reported to have evolved through continuing education and specialization programs 343 
towards supporting patient and medication safety initiatives (Figure 5). 344 
 345 
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These reported developments in pharmacists’ performance in Finnish hospitals can be considered as result 346 
of various contributing factors.   This quite fast extension of their tasks would not have  been possible 347 
without the support of national patient and medication safety initiatives and guidelines,23-24,27,47 348 
pharmacists’ involvement in establishing these policies, and making long-term continuing education 349 
available for pharmacists with the focus on systems approach to patient and medication safety.38,45 The first 350 
steps in creating awareness of medication safety risks and actual errors were taken  through a patient 351 
safety incident reporting system, which was implemented in Finland in 2007 in the first healthcare units,  as 352 
have  been recommended by international and national guidelines.4-7,23-24,28,47 Since then, reporting and 353 
learning from medication errors and related research have extended to more than 200 Finnish healthcare 354 
organizations,  revealing medication safety risks and their characteristics, which has laid the foundation for 355 
more prospectively managing the risks.25,39,48 This work has facilitated the clinical pharmacists’ participation 356 
in multiprofessional patient safety work, as has been suggested e.g., by the Council of Europe and EDQM.5-357 
6,8-9  358 
 359 
The system-based actions to improve medication safety that were reported to be widely performed by 360 
clinical pharmacists in Finnish hospitals in 2016 (Figure 3) cover well the crucial stages of the medication-361 
use process (Figure 4).  The actions reported to be performed are in line with the European hospital 362 
pharmacy statements, particularly with the statements concerning pharmacists ensuring quality assurance 363 
strategies for medicine use processes (5.2), reporting of adverse drug reactions and medication errors (5.4) 364 
and ensuring that the information needed for safe medicines use, including both preparation and 365 
administration, is accessible at the point of care (5.9).42  366 
 367 
During the five years, the most notable reported increase had happened with conducting medication 368 
reconciliations, e.g., on admission (+63%), despite not being reported as a future plan in 2011. Medication 369 
reconciliation was not explicitly mentioned as a concept in patient safety and medicines policy documents 370 
published in Finland in the beginning of the 2000s.23-24 In many other countries and international 371 
recommendations medication reconciliation has been prioritized as one of the key strategies to prevent 372 
adverse drug events and improve patient safety at all transitions in care.7,49 In the United States (US), 373 
medication reconciliation was recommended already in 2005 in the Hospitals’ National Patient Safety Goals 374 
established by the US Joint Commission on Accreditation of Healthcare Organizations which also 375 
established guidelines for performing medication reconciliation.50 In Europe, medication reconciliation has 376 
been prioritized e.g., by the second European Union (EU) patient safety and quality program (PASQ).11 377 
Despite recommendations and guidelines, medication reconciliation practices are challenging to perform 378 
and EAHP evaluated that it was the most poorly implemented statement (4.4) in Europe in 2015.42,51 The 379 
reasons for this were that pharmacists usually had no access to patient information systems or direct 380 
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contact to patients. In our survey in 2016, clinical pharmacists were reported to have  access to patient 381 
records in almost all (96%) responding units, which is in line with the European hospital pharmacy 382 
statements (statement 4.3).42  Pharmacists should also ensure accurate recording of all allergy and other 383 
relevant medicine-related information in the patient’s health record (5.8).42 The importance of reconciled 384 
medication charts has been identified recently in Finland in the Rational Pharmacotherapy Action Plan 385 
2018-2022 to be taken into account in the ongoing social and healthcare reform.26,52  386 
 387 
A positive development was reported in strategic planning and managing clinical pharmacy services in 388 
hospitals.  However, the content and quality of clinical pharmacy services are not uniform even inside the 389 
same organization. More than half of the responding units (52%) reported being familiar with the European 390 
Statements of Hospital Pharmacy42 in 2016. The Statements could be utilized to standardize the content 391 
and availability of clinical pharmacy services. Common future plans that were reported related to changing 392 
the focus of clinical pharmacists’ role on patient-oriented tasks instead of drug logistics. Automation 393 
technology (e.g., automated dispensing systems) which is arriving in Finnish hospitals, was expected to 394 
release clinical pharmacists’ time from logistic tasks to providing pharmaceutical care services that improve 395 
medication safety.53 Furthermore, the Finnish healthcare reform52 will enable the reform of current 396 
legislation54 related to the number of hospital pharmacies with overlapping responsibilities.53 This will also 397 
release hospital pharmacy staff for patient care. It is crucial to be prepared with clinical pharmacy skills to 398 
be able to provide pharmaceutical care at this point.  399 
 400 
Pharmacists’ participation in long-term continuing education, related to pharmaceutical care and system-401 
based medication safety work, was reported to be increased during the five years (Figure 5). The majority 402 
(70 %) of the respondents reported that they are able to satisfactorily use their expertise achieved from 403 
long-term continuing education and almost half (48 %) of the respondents thought that continuing 404 
education had helped them to adopt a more patient-oriented role. The history of long-term continuing 405 
education of clinical pharmacy and medication safety is fairly short in Finland: during the first decade of the 406 
21st century, the Faculty of Pharmacy in the University of Helsinki started systematic research and 407 
education about patient and medication safety issues. Clinical pharmacy oriented hospital pharmacy 408 
specialization program has been available since 2010.31,55 Post-graduate accreditation training for 409 
comprehensive medication review (CRM) started in 2005.37,56 Later also a shorter, one-year training for 410 
expertise in medication reviews and accreditation training for expertise in ward pharmacy has been 411 
available. The post-graduate clinical pharmacy specialization and accreditation training have facilitated the 412 
shift of clinical pharmacists’ tasks from drug logistics to patient-centered work. Furthermore, the education 413 
of basic degrees in pharmacy is under reform to meet the growing need for clinical pharmacy skills. The 414 
latter is also addressed in the European hospital pharmacy statement 6.1.42 415 
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 416 
The relative proportion of responding organizations which reported having evaluated the benefits or 417 
outcomes of clinical pharmacy services had increased from 16 % to 33% during 2011-2016.  According to 418 
the respondents, the most common evaluated and achieved benefits in 2016 were related to the work of 419 
nurses e.g. saved their working time, improved their pharmacotherapy skills and increased their 420 
collaboration with pharmacists (Figure 6). Also, savings in drug consumption, increased number of accurate 421 
medication charts and increased medication error reporting were common. However, only a few 422 
organizations had published their results nationally and international publications were missing. This area 423 
needs development, as is also pointed out in the European hospital pharmacy statements (6.4)42 and in the 424 
national Rational Pharmacotherapy Action Plan.57 Furthermore, documenting clinical pharmacy 425 
interventions for the patient’s health record, according to the European hospital pharmacy statement 4.342 426 
enables more effective outcomes research related to clinical pharmacy services’ impact on e.g. 427 
readmissions, treatment periods and mortality. Hospital pharmacists should be encouraged and educated 428 
for measuring and studying outcomes of clinical pharmacy services to achieve more rigorous evidence. 429 
 430 
4.1 Strengths and limitations 431 
The results of this national study can be generalized for hospital inpatient care in Finland even though the 432 
overall response rates were moderate (60% in 2011 and in 52% in 2016).  Despite the moderate response 433 
rates, the coverage of the responses in terms of the coverage of the largest inpatient units with hospital 434 
pharmacies were 83% in 2011 and 75% in 2016. The survey method was applicable to study national 435 
development for strategic management purposes as in other follow-up survey studies in US19 and Europe22, 436 
even though it has methodical limitations e.g. compared to using actual performance data or observation 437 
method.  The target group of the survey was knowledgeable for providing data of the recent developments 438 
and the status of the clinical pharmacy services.  Addressing the survey to all hospital clinical pharmacists 439 
would be interesting in the future. Clinical pharmacy services’ impact on patient care outcomes should also 440 
be followed up with more rigorous methods. 441 
 442 
4.2 Clinical and practical implications 443 
Evolution of clinical pharmacy services to ensure medication safety and their impact on patient care 444 
outcomes should be followed-up regularly also in the future. In 2016, more than half (62%) of the 445 
responding organizations thought that pharmacists could be working as medication safety officers in the 446 
future. The first post for a medication safety officer (pharmacists) was launched in Finland in 2017 in the 447 
Helsinki University Hospital. A national focal point for coordinating medication safety research, practice and 448 
competence development should be established26,58-59 as has been recommended by the Council of Europe 449 
already in 20065-6, and repeated by other key documents guiding patient and medication safety work. 450 
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 451 
 452 
 453 
 454 
5. CONCLUSIONS 455 
Pharmacists’ involvement in patient care and system-based medication safety work was reported to 456 
become more common and planned in Finnish hospitals during 2011-2016. This development is in line with 457 
international and national system-based patient safety guidelines and policy initiatives and should be 458 
continued. Availability of patient-centered and system-based continuing education and accreditation 459 
training has had important impact in this shift towards patient-oriented services. 460 
 461 
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Table 1. Clinical pharmacy services in hospital pharmacies and medicine dispensaries responding the surveys in 2011 
(n=71/118) and 2016 (n=27/52). It should be noted, that the total number of medicine dispensaries has remarkably 
decreased during 2011-2016 in Finland, while the number of hospital pharmacies has remained the same.  
Clinical pharmacy services  
2011 (n=71) 
n (%) 
2016 (n=27) 
n (%) 
Responding units not providing clinical pharmacy services 35 (49%) 4 (15%) 
Responding units providing clinical pharmacy services 
- hospital pharmacies 
- medicine dispensaries 
36 (51%) 
16 (44%) 
20 (56 %) 
23 (85%) 
17 (74%) 
6 (26%) 
Reported number of full-time* working clinical pharmacists 103 134-215** 
Reported number of part-time working clinical pharmacists 54 13-65** 
Reported number of hospital units receiving full-time* clinical pharmacy services 108 179-201** 
Reported number of hospital units receiving part-time clinical pharmacy services 134 192-236** 
Responding units having a manager, whose working time was dedicated to 
management of clinical pharmacy services 
30 (42%) 20 (74%) 
Responding units having a plan or strategy for clinical pharmacy services 14 (20%) 17 (63%) 
*Full-time = office hours from 8:00 a.m. to 4:00 p.m. during week days.  
**Ranges were used in the 2016 survey and actual numbers were asked in the 2011 survey. 
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Figure 1. Content of the survey instrument in 2016. 
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Figure 2. Location of the hospital pharmacies and medicine dispensaries that responded to the survey in 2016 
(n=27/52) by county. 
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Figure 3.  Reported tasks of clinical pharmacists (%) in 2011 and 2016. *New tasks (n=12) added to the year 2016 
survey. 
 
 
Figure 4.  Illustration of the evolution of the tasks of the clinical hospital pharmacists in Finland by 2016 as reported by 
the responding hospital pharmacies and medicine dispensaries. The figure illustrates the coverage of the clinical 
pharmacy services of the stages of medication use process by applying Reason’s Swiss Cheese Model.
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Figure 5. Participation in long-term continuing education and accreditation training of one or more of the clinical 
pharmacists in the responding units (%). Other (n=4): expertise in patient safety (n=2), master of clinical pharmacy 
(n=1), hospital’s internal continuing education program (n=1). Training for expertise in medication reviews was not yet 
provided in 2011. 
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Figure 6. Benefits and outcomes of clinical pharmacy services that were reported to been assessed and achieved in 
33% (n=9/27) of the responding units in 2016. 
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